1. Short title This Act may be cited as the John W. Walsh Alpha-1 Home Infusion Act of 2023 . 2. Medicare coverage of Alpha-1 Antitrypsin Disorder treatment (a) In general Section 1861 of the Social Security Act ( 42 U.S.C. 1395x ) is amended— (1) in subsection (s)(2)— (A) by striking and at the end of subparagraph (II); (B) by inserting and at the end of subparagraph (JJ); and (C) by inserting at the end the following new subparagraph: (KK) Alpha-1 Antitrypsin Deficiency Disorder treatment (as defined in subsection (nnn)); ; and (2) by adding at the end the following new subsection: (nnn) Alpha-1 Antitrypsin Deficiency Disorder treatment (1) The term Alpha-1 Antitrypsin Deficiency Disorder treatment means augmentation therapy (as defined in paragraph (2)(C)) furnished by qualified home infusion therapy suppliers (as defined in paragraph (2)(D)) which are furnished in the individual’s home (as defined in paragraph (2)(B)) to an individual— (A) who is under the care of an applicable provider; (B) who is enrolled under both parts A and B of this title, and is not enrolled in an MA plan under part C of such title; and (C) who requires augmentation therapy (as defined in paragraph (2)(C)). (2) For purposes of this subsection: (A) The term applicable provider means— (i) a physician; (ii) a nurse practitioner